Cureveda LLC was co-founded in 2010 by Johns Hopkins Bloomberg School of Public Health faculty members Shyam Biswal and Rajesh Thimmulappa together with Christy Wyskiel. The company is focused on the discovery, development and commercialization of drugs for the treatment of inflammatory, autoimmune and neurogenerative diseases. Cureveda is developing Nrf2 activators for the treatment of a number of disease indications including chronic obstructive pulmonary disorder, multiple sclerosis and ulcerative colitis. The Company is also developing Nrf2 activators as medical countermeasures to treat radiation exposure.
